{"id":742045,"date":"2010-11-09T14:46:00","date_gmt":"2010-11-09T14:46:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\/"},"modified":"2026-08-10T13:01:14","modified_gmt":"2026-08-10T17:01:14","slug":"merck-wins-temodar-patent-infringement-lawsuit-on-appeal","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\/","title":{"rendered":"Merck Wins TEMODAR\u00ae Patent Infringement Lawsuit on Appeal"},"content":{"rendered":"<p>WHITEHOUSE STATION, N.J.&#8211;(BUSINESS WIRE)&#8211;Merck &amp; Co., Inc. said today that a federal appellate court ruled in its        favor in a TEMODAR patent infringement suit against Barr Laboratories,        an affiliate of Teva Pharmaceuticals.     <\/p>\n<p>       By a 2-1 vote, the appellate court rejected Barr&#8217;s arguments and        reversed a lower court ruling that the U.S. patent was unenforceable.     <\/p>\n<p>       &#8220;The court appropriately ruled that the patent for TEMODAR in the U.S.        is enforceable,&#8221; said Bruce N. Kuhlik, executive vice president and        general counsel of Merck. &#8220;We invest heavily in R&amp;D to discover        innovative medicines like TEMODAR, and we will vigorously defend our        intellectual property rights.&#8221;     <\/p>\n<p>       Teva had been seeking FDA approval to sell a generic version of the 5,        20, 100, 140, 180 and 250 mg capsules of TEMODAR. In connection with        Teva&#8217;s prior agreement not to launch during the appeal, Merck agreed        that it will not object to Teva&#8217;s launch of a generic version of TEMODAR        in August 2013. The U.S. patent and exclusivity periods otherwise will        expire on February 2014.     <\/p>\n<p>       Schering Corporation filed the patent infringement lawsuit against Barr        in July 2007. A trial was held in U.S. District Court for the District        of Delaware in October 2009.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com&amp;esheet=6505164&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=1&amp;md5=af791a34f905c0711bd7b56be5559b64\">www.merck.com<\/a>.     <\/p>\n<p>       <b>Forward Looking Statement<\/b>     <\/p>\n<p>       This statement includes \u201cforward-looking statements\u201d within the meaning        of the safe harbor provisions of the United States Private Securities        Litigation Reform Act of 1995. Such statements may include, but are not        limited to, statements about the benefits of the merger between Merck        and Schering-Plough, including future financial and operating results,        the combined company\u2019s plans, objectives, expectations and intentions        and other statements that are not historical facts. Such statements are        based upon the current beliefs and expectations of Merck\u2019s management        and are subject to significant risks and uncertainties. Actual results        may differ from those set forth in the forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that the expected synergies from the merger of Merck and        Schering-Plough will not be realized, or will not be realized within the        expected time period; the impact of pharmaceutical industry regulation        and health care legislation; the risk that the businesses will not be        integrated successfully; disruption from the merger making it more        difficult to maintain business and operational relationships; Merck\u2019s        ability to accurately predict future market conditions; dependence on        the effectiveness of Merck\u2019s patents and other protections for        innovative products; the risk of new and changing regulation and health        policies in the U.S. and internationally and the exposure to litigation        and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2009 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=6505164&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=780e11b9429c27a15c6f15e205622b4d\"><span class=\"bwuline\">www.sec.gov<\/span><\/a>).     <\/p>\n<p class=\"bwalignc\">\n<p><p>       Merck &amp; Co., Inc.<br \/>Media:<br \/>Ron Rogers, 908-423-6449<br \/>or<br \/>Investor:<br \/>Joe        Romanelli, 908-423-5088     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc. said today that a federal appellate court ruled in its favor in a TEMODAR patent infringement suit against Barr Laboratories, an affiliate of Teva Pharmaceuticals. By a 2-1 vote, the appellate court rejected Barr&#8217;s arguments and reversed a lower court ruling that the U.S. patent was unenforceable. &#8220;The court appropriately ruled that the patent for TEMODAR in the U.S. is enforceable,&#8221; said Bruce N. Kuhlik, executive vice president and general counsel of Merck. &#8220;We invest heavily in R&amp;D to discover innovative medicines like TEMODAR, and we will vigorously defend our intellectual property rights.&#8221; Teva had been seeking FDA approval to sell a generic version of the 5, 20, 100, 140, 180 and 250 mg capsules of TEMODAR. In connection with Teva&#8217;s prior agreement not to launch during the appeal, Merck agreed that it will not object to Teva&#8217;s launch of a generic version of TEMODAR in August 2013. The U.S. patent and exclusivity periods otherwise will expire on February 2014.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742045","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Wins TEMODAR\u00ae Patent Infringement Lawsuit on Appeal - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Wins TEMODAR\u00ae Patent Infringement Lawsuit on Appeal - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. said today that a federal appellate court ruled in its favor in a TEMODAR patent infringement suit against Barr Laboratories, an affiliate of Teva Pharmaceuticals. By a 2-1 vote, the appellate court rejected Barr&#039;s arguments and reversed a lower court ruling that the U.S. patent was unenforceable. &quot;The court appropriately ruled that the patent for TEMODAR in the U.S. is enforceable,&quot; said Bruce N. Kuhlik, executive vice president and general counsel of Merck. &quot;We invest heavily in R&amp;D to discover innovative medicines like TEMODAR, and we will vigorously defend our intellectual property rights.&quot; Teva had been seeking FDA approval to sell a generic version of the 5, 20, 100, 140, 180 and 250 mg capsules of TEMODAR. In connection with Teva&#039;s prior agreement not to launch during the appeal, Merck agreed that it will not object to Teva&#039;s launch of a generic version of TEMODAR in August 2013. The U.S. patent and exclusivity periods otherwise will expire on February 2014.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\\\/\",\"name\":\"Merck Wins TEMODAR\u00ae Patent Infringement Lawsuit on Appeal - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2010-11-09T14:46:00+00:00\",\"dateModified\":\"2026-08-10T17:01:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Wins TEMODAR\u00ae Patent Infringement Lawsuit on Appeal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Wins TEMODAR\u00ae Patent Infringement Lawsuit on Appeal - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\/","og_locale":"en_US","og_type":"article","og_title":"Merck Wins TEMODAR\u00ae Patent Infringement Lawsuit on Appeal - Merck.com","og_description":"Merck &amp; Co., Inc. said today that a federal appellate court ruled in its favor in a TEMODAR patent infringement suit against Barr Laboratories, an affiliate of Teva Pharmaceuticals. By a 2-1 vote, the appellate court rejected Barr's arguments and reversed a lower court ruling that the U.S. patent was unenforceable. \"The court appropriately ruled that the patent for TEMODAR in the U.S. is enforceable,\" said Bruce N. Kuhlik, executive vice president and general counsel of Merck. \"We invest heavily in R&amp;D to discover innovative medicines like TEMODAR, and we will vigorously defend our intellectual property rights.\" Teva had been seeking FDA approval to sell a generic version of the 5, 20, 100, 140, 180 and 250 mg capsules of TEMODAR. In connection with Teva's prior agreement not to launch during the appeal, Merck agreed that it will not object to Teva's launch of a generic version of TEMODAR in August 2013. The U.S. patent and exclusivity periods otherwise will expire on February 2014.","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:14+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\/","name":"Merck Wins TEMODAR\u00ae Patent Infringement Lawsuit on Appeal - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2010-11-09T14:46:00+00:00","dateModified":"2026-08-10T17:01:14+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-temodar-patent-infringement-lawsuit-on-appeal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Wins TEMODAR\u00ae Patent Infringement Lawsuit on Appeal"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"45d019de-0e9c-4f8e-8828-1c422fe82a2f","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742045\/revisions"}],"predecessor-version":[{"id":3679183,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742045\/revisions\/3679183"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742045"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}